2026, FDA and Health Outcomes - Health Care Compliance Brief

Intelerad Acquires PenRad Technologies, Inc., Expanding Breast Imaging and Lung Screening Capabilities

Healthcare IT Today

AUGUST 26, 2022

The acquisition will expand Intelerad’s product offerings for mammography and lung analytics, optimizing workflows for radiologists and boosting health outcomes for patients. billion by 2026. (PenRad), a software provider for enhancing productivity for breast imaging and lung screening. About Intelerad.

Patient Satisfaction

Patient Satisfaction Health Outcomes COVID-19 FDA

Using Machine Learning in the Evolving Landscape of Real-World Data

HIT Consultant

DECEMBER 8, 2021

between now and 2026. In fact, in January 2021, the FDA released an Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan, a clear indication of the technology’s explosive growth and legitimacy within healthcare. Zeynep Icten, Ph.D., Director of Data Science Solutions at Panalgo.

FDA

FDA Health Outcomes Medicaid Medicaid

CMS Promotes Competition, Transparency, Health Equity and More in the CY2025 Medicare Advantage and Part D Proposed Rule

Healthcare Law Blog

NOVEMBER 13, 2023

A chronically ill enrollee is defined as an MA member with one or more complex chronic conditions, who is at risk for hospitalization or other adverse health outcomes, and who requires intensive care coordination.

Medicare

Medicare Medicare Medicaid Medicaid

Intelerad Acquires PenRad Technologies, Inc., Expanding Breast Imaging and Lung Screening Capabilities

Using Machine Learning in the Evolving Landscape of Real-World Data

CMS Promotes Competition, Transparency, Health Equity and More in the CY2025 Medicare Advantage and Part D Proposed Rule

Stay Connected